CardioWise™ Welcomes Geoffrey Dalbow as Chief Technology Officer
Healthcare Technology Innovator Brings Experience in the Research and Development of Imaging Solutions to New Cardiac Diagnostic Imaging Company
FAYETTEVILLE, Ark.– March 15, 2013 – Geoffrey Dalbow has recently joined Cardiowise, Inc. as Chief Technology Officer. His background includes substantial leadership experience in the highly competitive area of medical technology. Through the application and optimization of emerging imaging technologies, he has delivered solutions that improved health care quality, safety and efficiencies, while reducing the cost of care. During his career, Mr. Dalbow has directed multiple research and development efforts delivering a broad range of products and solutions to improve healthcare. He managed and secured more than 80 patents for R2 Technology in the area of Computer Aided Detection technology. His business experience is international in scope and includes India, China and the Middle East as well as South America.
Mr. Dalbow comes to CardioWise from CMS, Roper Industries where he was recently employed as the CTO and Director of Business Development. Prior to Roper, Geoffrey was the Director of Research and Development for Philips Medical Systems. Previous to that, Dalbow and a team of technology experts established R2 Technology, where he directed the research and development of medical solutions for computer aided detection and diagnosis of cancer. In only three years, in his position as CTO, the company was taken from startup to market share leader and was successfully sold. Prior to R2 Technologies, Mr. Dalbow held several leadership positions with Varian Medical Systems. His wealth of imaging and product development expertise provides Cardiowise with the leadership needed to build the company’s innovative development and growth platform.
Mr. Dalbow received his Bachelor of Science from Carnegie Mellon University and completed numerous courses towards his Ph.D. in Medical Physics at the University of Pittsburgh. He has held management positions in several companies on the Forbes Best Managed Companies Top 100 List. Mr. Dalbow received the Company Leadership Award from Medical Imaging Magazine, presented a white paper to federal governing bodies, and has had articles published in industry trade magazines.
In his address at the World Health Organization (WHO) conference in Paris, Mr. Dalbow gave the presentation “Device Improvements to Reduce the Number of Under-Doses and Over-Doses and Misaligned Exposures from Therapeutic Radiation.” He has spoken at an FDA annual meeting on Meeting Standardization of Treatment Prescriptions for Oncology, as well as contributed to Computer Assisted Radiology and Surgery white papers on Just in Time Health Care. Dalbow has also managed multiple FDA submissions, including both 501k and PMA submissions. He remains engaged in emerging issues in health care, is dedicated to reducing costs through innovation, and is an industry chair for The Medical Imaging & Technology Alliance (MITA).
CardioWise™ is commercializing patent-pending, non-invasive Cardiac Magnetic Resonance Imaging (cMRI) analysis software that produces a quantified 3D image model of the human heart, called Multiparametric Strain (MPS™) heart analysis. CardioWise heart analysis software combined with cardiac MRI is a single diagnostic test that is able to provide quantitative analysis of the myocardium, arteries and valves with an unprecedented level of detail. It has the opportunity to become the new gold standard of care for heart health analysis. CardioWise™ is a VIC Technology Venture Development™ portfolio company.